Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tregalizumab in Allergic Asthma
NCT04673591Phase 2Completed
- Sponsor
- T-Balance Therapeutics
- Start
- Dec 2020
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic asthma comparing Tregalizumab with Placebo (2 arms). Primary endpoint: Baseline-corrected late asthmatic response (AUC FEV1) at Day 84. Started Dec 2020; status: completed.
02
Drugs
tregalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT04673591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04673591.